Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГУ Московский НИИ психиатрии Росздрава; 2ГУ НИИ ревматологии РАМН, Москва
Список исп. литературыСкрыть список 1. Гусева Н.Г. Системная склеродермия. 1993. 2. Гусева Н.Г.Системная склеродермия и склеродермическая группа болезней. Рус. мед. журн. 1998; 6 (8). 3. Angelopoulos NV, Moutsopoulos AA. Psychiatric symptoms associated with scleroderma. Psychother Psychosomat 2001; 70: 145–50. 4. Baubet T et al. Psychiatric manifestations of systemic sclerosis. Ann Med Interne 2002; 153 (4): 237–41. 5. Bell C, Coupland N, Creamer P. Digital infarction in a patient with Raynaud\'s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology 1996; 47: 901–3. 6. Benrud-Larson LM et al. Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol 2003; 22 (2): 130–9. 7. Benrud-Larson LM et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002; 95 (3): 267–75. 8. Beretta et al. Determinants of depression in 111 Italian patients with systemic sclerosis. Reumatismo 2006; 58 (3): 219–25. 9. Bond CH. Am Brit J Psychiat 1897; 43: 174–85. 10. Chen Y, Huang JZ, Qiang Y et al. Investigation of stressful life events in patients with systemic sclerosis. J Zhejiang Univ Sci B 2008; 9 (11): 853–6. 11. Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud\'s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology Oxford 2001; 40: 1038–43. 12. Cutolo M, Prete C, Walker J. Is stress a factor in the pathogenesis of autoimmune rheumatic diseases? Clin Exper Rheumat 1999; 17: 515–8. 13. David M. A case of scleroderma mentioned by Hippocrates in his aphorisms. Korot 1981; 8 (1–2): 61–3. 14. Danieli E, Airo P et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 48–54. 15. Dercum MD. Scleroderma. J Nerv Mental Dis 1896; 21 (Issue 7). 16. Edwards RR et al. Catastrophising, pain, and social adjustment in scleroderma: relationships with educational level. Clin J Pain 2006; 22 (7): 639–46. 17. Fantonetti G. Case of general induration of the skin. Dublin J Med Sci 1838; 13: 158–9. 18. Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29 (2): 427–39. 19. Hui KK, Johnston MS, Brodsky M et al. Scleroderma, Stress and CAM Utilization. Evid. Based Complement. Altern Med 2007; 25. 20. Johnson EO, Moutsopoulos H. Neuroendocrine manifestations in Sjogren\'s syndrome: relation to the neurobiology of stress. Ann N Y Acad Sci 2000; 917: 797–808. 21. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN et al. Hypofunction of the stress axis in Sjogren syndrome. J Rheumatol 1998; 25: 1508–14. 22. King M et al. Psychological problems in patients with scleroderma: A controlled, prospective study. Psychology Health Med 1996; 1 (Issue 3): 249–57. 23. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthrit Rheumat 1998; 41 (5): 778–99. 24. Lee P. Systemic sclerosis following physical trauma. J Rheumatol 1996; 23: 1689–90. 25. Legendre C, Allanore Y, Ferrand I, Kahan A. Evaluation of depression and anxiety in patients with systemic sclerosis. Joint Bone Spine 2005; 72 (5): 408–11. 26. Matsuura E, Ohta A, Kanegae F et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003; 30: 1782–7. 27. Moser DK et al. Predictors of psychosocial adjustment in systemic sclerosis. Arthrit Rheum 2005; 36 (Issue 10): 1398–405. 28. Moser DK, Clements PJ, Brecht ML, Weiner SR. The influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthrit Rheum 1993; 36: 1398–405. 29. Mozzetta A et al. Mental health in patients with systemic sclerosis: a controlled Investigation. J Compilat 2008; 22: 336–40. 30. Nietert PJ et al. Correlates of depression, including overall and gastrointestinal functional status among patients with systemic sclerosis. J Rheumatol 2005. 31. Paquette DL, Falanga VJ. Cutaneous concerns of scleroderma patients. J Dermatol 2003; 30 (6): 438–43. 32. Richards HL, Herrick AL, Griffin K. Psychological adjustment to systemic sclerosis–exploring the association of disease factors, functional ability, body related attitudes and fear of negative evaluation. Psychol Health Med 2004; 9 (Issue 1): 29–39. 33. Richards H, Herrick A, Griffin K et al. Systemic sclerosis: patient\'s perceptions of their condition. Arthrit Rheum 2003; 49: 689–996. 34. Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. 1996 Arthrit Rheum 1996; 39 (Issue 6): 1035–40. 35. Silman A. Epidemiology of scleroderma. Ann Rheum Dis 1991; 50: 846–53. 36. Santavirta N, Konttinen YT, Tornwall J et al. Neuropeptides of the autonomic nervous system in Sjorgen syndrome. Ann Rheum Dis 1997; 56: 737–40. 37. Thombs BD, Fuss S, Hudson M et al. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. Arthrit Rheum 2008; 59 (3): 431–7. 38. Thombs BD, Hudson M, Taillefer SS, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthrit Rheum 2008; 59 (4): 504–9. 39. Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with systemic sclerosis: A systematic review of the evidence. Arthrit Rheum 2007; 57 (6): 1089–97. 40. Waheed A et al. The burden of anxiety and depression among patients with chronic rheumatologic disorders. J Pak Med Assoc 2006; 56 (5): 243–6.